Further investigation involving in vitro and in vivo experiments, online datasets, and online predicting tools has revealed that lncRNA XIST serves as a ceRNA for miR-34a by sponging miR-34a, and competing with MET for miR-34a binding, hence modulated thyroid cancer cell proliferation and tumor growth (Liu et al., 2018). The gene discussed is MET; the disease is thyroid gland carcinoma.